Pharmacological agents that mimic incretin activity or combine actions of multiple incretins have demonstrated significant metabolic benefits, including improved glycemic control, enhanced insulin sensitivity, reduction in hepatic steatosis, and meaningful weight loss [91]. This evidence concerns the gene INS and fatty liver disease.